BioNTech selects Rwanda, Senegal for potential malaria and tuberculosis mRNA vaccine manufacturing

BioNTech selects Rwanda, Senegal for potential malaria and tuberculosis mRNA vaccine manufacturing

Source: 
Fierce Pharma
snippet: 

BioNTech hopes it can follow up its global COVID-19 success with the world’s first mRNA vaccines against malaria and tuberculosis. While still under development, the German biotech is already eyeing two African countries to scale up production for the potential shots.